Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

Study Overview
=================
Brief Summary
-----------------
This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.

Detailed Description
-----------------
The study will include hospitalized, moderate COVID-19 cases that have a risk of respiratory failure. The study will generally consist of: A short screening phase (1 day) before enrollment and thus treatment decision. A 21 day treatment phase with one cycle of palbociclib An up to day 90 Safety Follow-Up Phase The first three patients will be enrolled and treated one by one; the independent safety data review committee (ISRC) will review each patient after D21 before enrollment of the subsequent patient is permitted.

Official Title
-----------------
Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Palbociclib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >= 18 years positive PCR COVID-19 test (max. 72h old) known vaccination status ANC >= 1,000/mm3 and platelets >= 50,000/mm3 willingness to participate (written informed consent) established risk factors for a severe course of COVID-19-disease, for example: adipositas, cardiovascular disease including arterial hypertension, advanced age > 60, chronic lung disease including asthma, diabetis type I or II, chronic kidney disease, chronic liver disease Oxygen supply: ≤ 2 liters/minute Women of childbearing potential (WOCBP): must have a negative pregnancy test (ß- HCG urine or serum test) a. WOCBP is considered as i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. b. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. c. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Use of highly effective contraception method All potentially fertile participants, or their male partners, must use an adequate, medically approved method of contraception or agree to abstinence during and at least 3 weeks (females) and 14 weeks (males) after treatment with Palbociclib. For females, highly effective birth control should be used, i.e., combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, or intrauterine hormone-releasing system, bilateral tubal occlusion and vasectomized partner. As there is no information available on the interaction of palbociclib with oral contraceptives, a double-barrier contraception is necessary in this case. Males must agree to use a condom for at least 14 weeks after the treatment phase. Exclusion Criteria: age < 18 year ECOG >= 3 ANC < 1,000/mm3 and platelets < 50,000/mm3 intensive care patient treatment with any other CDK4/6 Inhibitor pregnant or breast-feeding women patients receiving immunosuppressants for other diseases (e.g. rheumatoid arthritis) known malignancy in the past 5 years other than basal cell carcinoma baseline O2-Saturation < 92% participation in any other medical device or medicinal product study within the previous month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Palbociclib<br>125 mg of palbociclib once daily for 21 consecutive days | Drug: Palbociclib<br>* 125 mg of palbociclib once daily for 21 consecutive days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of treatment-related treatment discontinuation after 21 days of palbociclib treatment |  | 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to freedom from oxygenation, measured in days after the first treatment dose. |  | 90 days | 
| Time to transfer to ICU |  | 90 days | 
| Course of neutrophil cell count during treatment |  | 21 days | 
| Course of D-dimer during treatment |  | 21 days | 
| Rate of thrombotic events during treatment |  | 21 days | 
| Course of O2 saturation during treatment |  | 21 days | 
| Rate of persisting symptoms after 3, 6, 9 and 12 months |  | Through completion of safety follow-up up to 12 month | 
| Dose reduction rate |  | 21 days | 
| Rate of (S)AEs at day 21 |  | at day 21 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, moderate, hospitalized, Palbociclib, CDK4/6 inhibition